Lipodermatosclerosis Diagnosis and Management

Clinical Presentation and Pathophysiology

Lipodermatosclerosis is a specific clinical sign of post-thrombotic syndrome (PTS) and chronic venous insufficiency, appearing as a combination of edema, redness, hyperpigmentation, and indurated skin changes in the lower extremities, according to the American Heart Association 1, 2
The condition results from chronic venous hypertension, which plays a central role in the pathogenesis of these tissue changes, as reported by the American College of Cardiology 1
Lipodermatosclerosis represents CEAP classification C4b disease, indicating more advanced venous insufficiency with skin changes beyond simple pigmentation or eczema, as defined by the American Venous Forum 1

Lipodermatosclerosis indicates moderate-to-severe venous disease requiring intervention to prevent progression to ulceration, with the American Heart Association guidelines recognizing this as a clinical manifestation of post-thrombotic syndrome 1, 3
Patients with lipodermatosclerosis have significantly impaired quality of life, with severe PTS with ulcers costing $3,817 per patient in the first year, compared to $839 for mild to moderate disease, according to the American Heart Association 1

Patients typically have documented venous reflux with valve closure times exceeding 500 milliseconds at the saphenofemoral or saphenopopliteal junction, as measured by the Society of Vascular Surgery 1
The condition often coexists with other signs of chronic venous insufficiency, including telangiectasia, venous ectasia, and in severe cases, atrophie blanche or ulceration, as reported by the American College of Phlebology 1, 2